Unlike the previous admission due to overdose of SGLT2 inhibitors along with dipeptidyl peptidase-4 inhibitors and sulfonylureas, severe hypoglycemia was not observed during the clinical course. This evidence concerns the gene DPP4 and Hypoglycemia.